Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $249,146.56 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 7,072 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $35.23, for a total value of $249,146.56. Following the completion of the transaction, the chief executive officer directly owned 536,962 shares in the company, valued at $18,917,171.26. The trade was a 1.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ying Du also recently made the following trade(s):

• On Monday, June 30th, Ying Du sold 6,918 shares of Zai Lab stock. The stock was sold at an average price of $35.52, for a total transaction of $245,727.36.
• On Thursday, June 26th, Ying Du sold 23,669 shares of Zai Lab stock. The shares were sold at an average price of $36.13, for a total value of $855,160.97.
• On Tuesday, May 13th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $28.57, for a total transaction of $1,428,500.00.
• On Wednesday, May 14th, Ying Du sold 46,389 shares of Zai Lab stock. The stock was sold at an average price of $28.09, for a total transaction of $1,303,067.01.
• On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The shares were sold at an average price of $33.11, for a total transaction of $97,508.95.

Zai Lab Stock Up 2.6%

NASDAQ:ZLAB traded up $0.94 during trading hours on Friday, hitting $36.43. 581,960 shares of the company's stock traded hands, compared to its average volume of 911,726. The business's fifty day simple moving average is $33.71 and its two-hundred day simple moving average is $31.32. The firm has a market cap of $4.05 billion, a P/E ratio of -14.63 and a beta of 0.99. Zai Lab Limited Unsponsored ADR has a 52 week low of $16.01 and a 52 week high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.05. The firm had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative return on equity of 33.35% and a negative net margin of 60.26%. On average, analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Scotiabank started coverage on Zai Lab in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 target price for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a research report on Thursday, March 27th. JPMorgan Chase & Co. lifted their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, March 13th. Leerink Partners set a $75.00 price target on Zai Lab and gave the stock an "outperform" rating in a research note on Monday. Finally, Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Zai Lab currently has a consensus rating of "Moderate Buy" and an average target price of $54.28.

Institutional Investors Weigh In On Zai Lab

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Zai Lab in the fourth quarter worth $29,000. Pictet Asset Management Holding SA purchased a new stake in Zai Lab during the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Zai Lab in the 1st quarter worth about $75,000. Barclays PLC boosted its holdings in Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock valued at $97,000 after acquiring an additional 2,856 shares during the period. Finally, Advisors Preferred LLC purchased a new stake in shares of Zai Lab during the first quarter valued at $110,000. Hedge funds and other institutional investors own 41.65% of the company's stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.